EMEA-001501-PIP06-20

Table of contents

Key facts

Invented name
Dupixent
Active substance
dupilumab
Therapeutic area
Dermatology
Decision number
P/0394/2020
PIP number
EMEA-001501-PIP06-20
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Treatment of prurigo nodularis
Route(s) of administration
Subcutaneous use
Contact for public enquiries
Sanofi-Aventis Recherche & Développement

Tel. +33 169745695
E-mail: contact-us@sanofi.com

Decision type
W: decision granting a waiver in all age groups for all conditions or indications

Decision

Related content

How useful was this page?

Add your rating